Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trabecular meshwork mesenchymal stem cells (TM-MSCs) are a population of adult multipotent stem cells isolated from the trabecular meshwork tissue of the eye. These cells exhibit classic mesenchymal stem cell (MSC) characteristics, including the ability to adhere to plastic and differentiate into osteogenic, adipogenic, and chondrogenic lineages. In regenerative medicine research, particularly for Parkinson's disease, TM-MSCs are valued for their capacity to differentiate into dopaminergic neuron-like cells and secrete various neurotrophic factors. Their therapeutic potential lies in cell replacement and paracrine signaling, where transplanted cells may help restore dopamine levels in the striatum and provide neuroprotective support to existing neurons, thereby improving motor and cognitive symptoms associated with neurodegeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trabecular meshwork mesenchymal stem cells.